Expert Interview
A Second View: Discussing the recent phase 2 results from infigratinib in children with achondroplasia and how it may compare to Biomarin's Voxzogo (vosoritide)
Ticker(s): BBIO, BMRNInstitution: OHSU
- Professor and Chair (emeritus) of Pediatrics, Oregon Health & Science University
- Has treated patients with achondroplasia for 40 years, currently involved in treatment decisions for 6 patients.
- Internationally renowned authority on the endocrine basis of growth and development and has been at the forefront of understanding the biology of growth hormone (GH) and growth factors for over 30 years.
How many patients do you manage with achondroplasia?
Added By: wilson_adminHave you prescribed Voxzogo?
Added By: wilson_adminWhat advantages (if any) do you see infigratinib having over Voxzogo (vosoritide)?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
